Search research articles
Contact Us
Filters
Showing results (111-120 of 147) with videos related to
Page
of 15
Sort By:
Cancer Cell
|
February 26, 2022
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Namrata S Patil, Barzin Y Nabet, Sören Müller, et al.
Cell Reports. Medicine
|
November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy
Yulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 4, 2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials
Roy S Herbst, Hen Prizant, Daniel Ruderman, et al.
Plos One
|
October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Nature Biotechnology
|
May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh, Anthony Lima, Rafael Molina, et al.
Oral Oncology
|
August 19, 2019
Immune profiles in primary squamous cell carcinoma of the head and neck
Vassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, et al.
Plos One
|
January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2012
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier
Laurent Salphati, Timothy P Heffron, Bruno Alicke, et al.
Journal of Medicinal Chemistry
|
January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors
Steven T Staben, Jianwen A Feng, Karen Lyle, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 147) with videos related to
Sort By:
Page
of 15
Cancer Cell
|
February 26, 2022
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Namrata S Patil, Barzin Y Nabet, Sören Müller, et al.
Cell Reports. Medicine
|
November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy
Yulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 4, 2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials
Roy S Herbst, Hen Prizant, Daniel Ruderman, et al.
Plos One
|
October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Nature Biotechnology
|
May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh, Anthony Lima, Rafael Molina, et al.
Oral Oncology
|
August 19, 2019
Immune profiles in primary squamous cell carcinoma of the head and neck
Vassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, et al.
Plos One
|
January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John Moffat, Gabriele Schaefer, et al.
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2012
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier
Laurent Salphati, Timothy P Heffron, Bruno Alicke, et al.
Journal of Medicinal Chemistry
|
January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors
Steven T Staben, Jianwen A Feng, Karen Lyle, et al.
Page
of 15